ANTHEM

What Anthem Biosciences promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 14 tracked 4 delivered 0 missed 10 open
  • Revenue Growth (YoY) delivered, diluted said Q1 FY26 Promised: about 20% growth on a year-on-year basis Q1 FY27: Promise pertains to FY26, which is complete. Final verdict stands.
  • Revenue Growth (YoY) at risk said Q4 FY26 Promised: in the vicinity of 20% and more... in the coming years Q1 FY27: Q1 FY27 revenue declined YoY due to timing shifts. Management now guides for 'double-digit' growth for the full year, a softer tone than the original '20% and more' aspiration.
  • Unit-4 Phase 1 Commissioning on track said Q2 FY26 Promised: consistently commissioned in two years from now Q1 FY27: Timeline reaffirmed. Management states Unit 4 will be ready by the end of FY28, consistent with the original target.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 14 tracked commitments for Anthem Biosciences — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens